Female cancer survivors more likely to report cost-related non-adherence
the ONA take:
Significant gender differences in cost-related medication non-adherence (CRN) were found among cancer survivors after adjusting for differences in sociodemographic, health status, and insurance coverage, a new study published online ahead of print in the Journal of Cancer Survivorship.
Because it has been reported that cancer survivors delay or avoid necessary care due to costs, researchers sought to determine the prevalence of CRN by gender and other factors among cancer survivors.
For the study, researchers from the University of South Carolina Arnold School of Public Health, in Columbia, analyzed data from 15,159 cancer survivors. Of those, 7.4% of male and 12.5% of female survivors reported CRN.
Results showed that female cancer survivors were 27% more likely than males to report CRN. Researchers found that a higher number of comorbidities and activity limitations were associated with higher CRN rates for both males and females.
“Given the rapid increase in prescription drug costs, it is important to monitor closely the CRN in high-risk subgroups,” the authors conclude.
Significant gender differences in cost-related medication non-adherence were found among cancer survivors.
Sign Up for Free e-newsletters
- FDA Issues Warning for Rolapitant Injectable Emulsion in the Treatment of CINV
- Risk Factors for Arterial, Venous Thrombosis Differ in Polycythemia Vera
- Resolving Vaginal Dryness in Women With a History of Breast Cancer
- BRCA Mutation Improves Prognosis for 2-year Survival in Younger-onset TNBC
- Identifying the Psychosocial Needs of Young Adults With Metastatic Cancer
- Pertuzumab Regimen Approved for Adjuvant, Neoadjuvant Therapy in Specific Breast Cancers
- Common Oncologic Emergencies That Occur With Multiple Myeloma
- Artificial Sweeteners and Cancer Risk (Fact Sheet)
- Blueberry Extract May Boost Efficacy of Radiotherapy for Cervical Cancer
- Dietary Estrogens Reduced Efficacy of Novel Breast Cancer Therapy
- Partial Response Achieved With Atezolizumab, Cobimetinib in Pretreated CRC
- Novel Approach Can Improve Both Colorectal Cancer Screening Outcomes and Adherence
- Survival Outcomes in Relapsed Hepatocellular Carcinoma Improved With Cabozantinib
- OS Similar With Gemcitabine Plus S-1 vs Standard Therapy for Biliary Tract Cancer
- Feasibility and Outcomes of Modified Enhanced Recovery After Surgery for Nursing Management of Aged Patients Undergoing Esophagectomy
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|